Compare VVOS & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | CTXR |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 19.8M |
| IPO Year | 2020 | N/A |
| Metric | VVOS | CTXR |
|---|---|---|
| Price | $2.07 | $1.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.25 | $6.00 |
| AVG Volume (30 Days) | 123.1K | ★ 560.0K |
| Earning Date | 11-19-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,317,000.00 | N/A |
| Revenue This Year | $17.96 | N/A |
| Revenue Next Year | $55.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.76 | N/A |
| 52 Week Low | $1.98 | $0.65 |
| 52 Week High | $7.95 | $5.95 |
| Indicator | VVOS | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 41.91 |
| Support Level | $1.98 | $1.12 |
| Resistance Level | $2.28 | $1.20 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 25.71 | 0.00 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.